Recent

% | $
Quotes you view appear here for quick access.

Cytosorbents Corporation Message Board

tonysd44 12 posts  |  Last Activity: Jun 24, 2016 12:07 PM Member since: Jul 12, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Footnote from Dr. Chan's Form 4

    by z3peru Jun 24, 2016 10:45 AM
    tonysd44 tonysd44 Jun 24, 2016 12:07 PM Flag

    Curious how a Board of Directors determines the CEO of a company only achieved 10% of performance goals or criteria and still keep his position. This revelation underscores and reinforces the argument many here make that the company cannot prosper and grow with this management team--

    Sentiment: Hold

  • Reply to

    The more good news, the more SP goes down...

    by iome70 Jun 13, 2016 10:10 AM
    tonysd44 tonysd44 Jun 13, 2016 1:21 PM Flag

    Your an idiot- I'm long the stock, have been for seven years- Shed one-third of my holdings after we got whacked unnecessarily 25 to 1 and another one-third after last years March 31st announcement DC had gutted the sales team- Check the balance sheet- bleeding red and that won't change for years- Have you bothered to look at Zacks & other projections of future earnings- No net profit until 2019 at earliest - Besides, the street makes the argument for me- PPS is a dismal $4.30 which is a full $1.00 less than when we up listed eighteen months ago- and lackluster volume to boot- The reality is clear as the dunce cap sitting atop your head-

    Sentiment: Hold

  • Reply to

    The more good news, the more SP goes down...

    by iome70 Jun 13, 2016 10:10 AM
    tonysd44 tonysd44 Jun 13, 2016 12:35 PM Flag

    Iome:
    This is another solid building block to the Euro distribution foundation. However it's going to take a press release of monumental proportions to move the PPS in a dramatic fashion. And the only one I foresee is the announcement of big name partner with appropriate cash infusion for U.S. sales & ongoing trials. Otherwise we'll tread water for years as they won't be profitable for three to four years minimum and as REFRESH 1 has reminded us, management conducts trials at agonizingly slow pace.

    And before sheeptards pile on that I'm bashing, this is the one topic I've exchanged messages/concerns about with DC. To clear up any misconceptions, it's a 40 patient trial, however they will enroll up to 56 if necessary to find best fit for the end result they're wanting. Here's my concern, he believes the trial is moving along at comfortable, even rapid pace. So therein lies the problem- Perception and reality don't exactly share the same space.

    So in very late 2019 or much more likely mid- 2020 the company might be in position to earn enough to stop the required dilution/debt - and finish or be far enough along in REFRESH 2 to attract that partner on their terms- Until then, it's going to be slowing sledding-

    Sentiment: Hold

  • Reply to

    Fresneus /Exthera medical

    by riogrande44 Jun 6, 2016 6:43 PM
    tonysd44 tonysd44 Jun 8, 2016 12:18 AM Flag

    It may be a longer road than we've got - but not by much- - They're not going to pump $15 million and other resources into a company/product they're not going to use- Common sense tells you our relationship with Fresenius is already on shaky ground- Chan is the worst CEO I've seen in a long time-- He's had lead time to lock down robust deals with big name partners and been terribly ineffective at doing so--

    Sentiment: Hold

  • Reply to

    Fresneus /Exthera medical

    by riogrande44 Jun 6, 2016 6:43 PM
    tonysd44 tonysd44 Jun 8, 2016 12:10 AM Flag

    The word "sepsis" does appear in many other press releases. This is the beginning of the end for our much touted partnership with Fresenius. You really think they'd pump $15 million into a company/product to do nothing with it- Chan has completely screwed himself and investors with his inability to properly negotiate deals with interested big name parties-- He's an awful CEO - To see it any other way is being blind

    Sentiment: Hold

  • Reply to

    This has all the ingredients for a buy out

    by gittyup2009 May 25, 2016 3:52 PM
    tonysd44 tonysd44 May 29, 2016 5:18 PM Flag

    No one is buying your story - or mine right now either. I laid out a scenario in which an investor today would reap an annualized return of 50%+over next four years -- Who wouldn't jump at that chance? - Apparently very, very few retail or institutional investors as the abysmally low volume illustrates.

    And I don't believe it's from lack of exposure. As DC likes to trumpet they're now approved in 32 countries, it's in 100's of hospitals, increasing numbers of medical professionals are using & touting the device and DC has attended countless investment conferences over the seven years I've held the stock- More people than ever before are aware of the opportunity, yet it sits at a paltry $4.00 - Why? - Big money is leery of true ( not what you & DC sing) future revenue, the competence of management to bring the company to the next level in a timely manner and a host of other threats that would invite a buy-out of the proportions you envision- Time will tell

    Sentiment: Hold

  • Reply to

    This has all the ingredients for a buy out

    by gittyup2009 May 25, 2016 3:52 PM
    tonysd44 tonysd44 May 27, 2016 3:05 PM Flag

    Unfortunately that old inconvenient truth we call "math" likely slices your figure by 50% - and we're talking about when waking up from your daily Chan stupor four years from now. Zacks has the company earning $75 million from 2016-2019 - I think that's a longshot, but will roll with the overly positive forecast for sake of discussion- They also have them LOSING $20 million over the course of those four years. And with today's announcement regarding Refresh I and II its clear a 360 patient study won't be completed until end of 2019.

    So along comes big time pharma company at end of 2019 to conduct it's due diligence. They'll model a ten year financial return OF and ON investment. Given an annual 25% increase in sales starting with $28 million for 2019 the next ten years gross revenue would total approximately $1.17 billion- Take 62% of that and you've got $725 million. They want to see a 20% return so would offer $600 million for the company or approximately $20.00 per share- You might scoff at that number, still a very handsome four year return for investors who purchase today at $4.00.

    And I don't care that DC claims the filter targets a $20 billion market- The fatal flaw in EVERY sheeptards arguments are the words " Dr. Chan says" --

    Sentiment: Buy

  • Reply to

    Fellow Beloved's

    by pearsby09 May 13, 2016 8:47 AM
    tonysd44 tonysd44 May 17, 2016 2:38 PM Flag

    Congrats, you we're riding the momentum of John McAfee being named CEO - On May 9th it opened at .49cts and subsequently his hiring/investment in the company hit the wire. Imagine if we woke up to the announcement that someone like J. Craig Venter had taken an ownership interest and been named the acting CEO of Cytosorbents- The $4.00 we're saddled with today would be $25.00 in a heartbeat- Meanwhile our CEO releases financial documents that portend an annual operating loss of $8-$10 million dollars.

    CTSO goes nowhere with Chan at the helm-

    Sentiment: Hold

  • Reply to

    New Report From Zacks Good!

    by berthabluefish May 11, 2016 10:40 AM
    tonysd44 tonysd44 May 11, 2016 4:04 PM Flag

    You've obviously taken up residence as the new village idiot. It's the same ID I've had for years and used in 200+ postings. What you label as bashing, most experienced investors would dub reality. We crossed over to the NASDAQ eighteen months ago at $5.30. - We're down 20% from that point and I can see no reason why we'll return to it any time soon.

    By any normal standard of thinking and measurement, that's a grossly unsatisfactory performance by management. And if that loss doesn't open your eyes, then the abysmal daily trading volume should worry you. Their is no interest or buzz surrounding this company- and that's very precarious for the PPS --

    Sentiment: Hold

  • Reply to

    New Report From Zacks Good!

    by berthabluefish May 11, 2016 10:40 AM
    tonysd44 tonysd44 May 11, 2016 12:06 PM Flag

    According to Zacks ( and all others who follow the company) they are still losing money through 2019- The PPS will languish- I'm sure you realize time has value. Its an important element when determining rate of return on an investment. Unless they ink a big time partner with cash/employee infusion this will trade in a tight range for years to come-

    Sentiment: Hold

  • Reply to

    info is out and its good!

    by jjgb072000 May 9, 2016 4:20 PM
    tonysd44 tonysd44 May 10, 2016 3:02 PM Flag

    Depending on what your buy-in point was, you have every right to be worried. They don't have the muscle, money or seemingly the ability to get this company off the ground. Anyone who believes they can finish a 300 patient trial in 2019 is out of their mind- As previously mentioned, on every front and self imposed timeline they are grossly behind schedule. What happened to the large institutional investors Chan predicted would come wading in upon up listing? Another misfire. Every analyst that covers the company agrees they wont be profitable until at least 2019 - More debt & dilution- Unless their is a big name partnership announced with appropriate cash infusion, its easy to see why this stock plods along between $4.00-$5.00 for coming years-

    Sentiment: Hold

  • Reply to

    info is out and its good!

    by jjgb072000 May 9, 2016 4:20 PM
    tonysd44 tonysd44 May 10, 2016 12:51 AM Flag

    Jaxla: At least your finally seeing the light. This is a dead stock under current management. They posted sales of $1,032,000 in 3rd Qtr. of 2014 and now crowing about adding $600k to that number eighteen months later. They won't be profitable for years- and maybe never with this group in charge- Extremely late on all fronts- India, Russia, the rest of Europe, REFRESH trial - and especially with providing worthy reputable clinical data-- Pray for an $8.00 buy-out-

    Sentiment: Hold

CTSO
4.41+0.03(+0.68%)Jun 28 4:00 PMEDT